Fundly.ai, a Mumbai-based fintech startup building an AI-native distribution network for India's pharmaceutical secondary trade, has raised $4 million in a pre-Series A round led by existing investors Accel and Multiply, with participation from Rajeev Ahuja and other angel investors, the company announced on September 8, 2026. The round also included roughly $900,000 in venture debt from Alteria Capital, taking Fundly.ai's total disclosed funding beyond $7 million.
The company is targeting one of India's largest and most fragmented trade categories: pharmaceutical distribution, a market the company pegs at approximately Rs 2.5 lakh crore, running through a dense web of stockists, wholesalers and retail chemists whose ordering, payments and credit workflows remain largely manual. Fundly.ai's platform is designed to coordinate these currently disconnected processes — order placement, payment settlement and short-term credit extension — through a single digital layer aimed at the secondary trade between distributors and pharmacies.
Founder and chief executive Amit Chawla has framed the company's core problem as one of coordination failure rather than access failure: pharmacies and small distributors are not short of suppliers, but the process of ordering, reconciling payments and securing working-capital credit across dozens of relationships remains slow, paper-heavy and error-prone. By embedding credit directly into the ordering workflow, Fundly.ai aims to reduce the friction that keeps many pharmacy operators reliant on informal credit arrangements with individual distributors.
The venture-debt component of the round, provided by Alteria Capital, is notable in a fintech-adjacent business model that inherently requires working capital to extend credit to trade partners. Structuring part of the raise as debt rather than pure equity allows Fundly.ai to fund receivables growth without diluting existing shareholders as aggressively — a increasingly common approach among Indian embedded-finance startups operating in trade and distribution categories where capital intensity scales directly with transaction volume.
India's pharmaceutical distribution sector has drawn growing fintech and B2B commerce interest over the past two years, following similar digitisation waves in categories such as FMCG and construction materials trading. Investors argue that healthcare-adjacent trade combines resilient, non-discretionary demand with genuinely poor existing digital infrastructure — a combination that has proven attractive even as broader Indian venture funding has grown more selective and focused on capital efficiency over raw growth.
For India's pharmacy retail ecosystem, still dominated by independent chemists rather than organised chains, platforms like Fundly.ai represent a potential shift in how small operators access both inventory and short-term financing. If the model proves durable, it could extend a template already being tested across other B2B trade categories: using transaction data from digitised ordering to underwrite credit more accurately than traditional collateral-based lending allows, potentially widening formal credit access for thousands of small pharmacy and distribution businesses that have historically operated outside the reach of institutional finance.
